<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" version="2.0">
  <channel>
    <title>DSpace コミュニティ: A 医学部 = School of Medicine</title>
    <link>http://ir.fmu.ac.jp/dspace/handle/123456789/1</link>
    <description />
    <textInput>
      <title>コミュニティ サーチエンジン</title>
      <description>チャネルの検索</description>
      <name>検索</name>
      <link>http://ir.fmu.ac.jp/dspace/simple-search</link>
    </textInput>
    <item>
      <title>Measurement of Optic Nerve Blood Flow During Dissection of Parasellar Tumors</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/129</link>
      <description>タイトル: Measurement of Optic Nerve Blood Flow During Dissection of Parasellar Tumors
&lt;br/&gt;
&lt;br/&gt;著者: Aimi, Yuri; Saito, Kiyoshi; Nagatani, Tetsuya; Ito, Eiji; Watanabe, Tadashi; Wakabayashi, Toshihiko
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Neurosurgical review
&lt;br/&gt;
&lt;br/&gt;巻: 32
&lt;br/&gt;
&lt;br/&gt;号: 2
&lt;br/&gt;
&lt;br/&gt;開始ページ: 199
&lt;br/&gt;
&lt;br/&gt;終了ページ: 205
&lt;br/&gt;
&lt;br/&gt;抄録: The authors describe direct measurement of optic nerve blood flow and examine application of such monitoring to detect optic nerve ischemia during parasellar tumor surgery. Twenty-six patients requiring surgery for parasellar tumors were evaluated prospectively. Ophthalmologic examination was performed before and after surgery. The optic nerve blood flow was measured using a laser Doppler flowmeter before tumor dissection (initial ONBF) and after tumor removal (final ONBF). The waveform was analyzed by a data acquisition system. In 16 patients, initial ONBF could be measured (22 nerves; 8.9±0.9 ml/100 g/min). Final ONBF could be determined in all 26 patients (42 nerves; 10.8±0.7 ml/100 g/min). In the 22 nerves with initial measurements, final ONBF (11.3±0.6 ml/100 g/min) was significantly increased (p&lt;0.01). In 6 patients whose optic canal was unroofed, the optic nerve blood flow did not change immediately; nonetheless, an increase was prominent in the final phase (p&lt;0.05). In another 6 patients, a small vessel adjacent to the optic nerve was temporarily occluded. The optic nerve blood flow was reduced demonstrably in 3 and recovered quickly after reperfusion. Intraoperative optic nerve blood flow measurement may be useful as a real-time monitoring for prediction and prevention of intraoperative optic nerve ischemia.</description>
      <pubDate>Sun, 29 Mar 2009 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>香山雪彦 講演原稿集（2009～2010）</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/128</link>
      <description>タイトル: 香山雪彦 講演原稿集（2009～2010）
&lt;br/&gt;
&lt;br/&gt;著者: 香山, 雪彦
&lt;br/&gt;
&lt;br/&gt;注記: ここに掲載するのは香山雪彦が福島県立医科大学を定年退職する前の２年間に行った講演、あるいは特別講義の原稿です。同じ表題で話しても講演のたびに原稿は少しずつ違えていましたが、その場合は最も代表的と思うものを掲載しています。実際に話した時は原稿にない脱線も多かったのですが、それは含んでいません。&#xD;
香山の本職は神経生理学講座の教授で、その仕事の内容は脳の機能についての研究と教育です。しかし、その本職と関係しないところで、「福島お達者くらぶ」と若い人たちによって名付けられた、摂食障害の人たち（およびその家族の人たち）の自助的な活動を目的としたグループの運営スタッフを務めてきました。&#xD;
その両方の立場で考えてきたことを講演で話してきたのですが、私を講演に招いていただいた人の立場によってどちらが中心になるか、バランスが大きく違っています。この下に示す７つの主題の講演の主な対象は、次のとおりです。&#xD;
人文・社会科学系の教養課程・専門課程の学生諸君（１）&#xD;
自然科学系・工学系の教養課程の学生諸君（２）&#xD;
脳機能を扱う専門職の人たちおよびその課程の学生諸君（３）&#xD;
医療系への進学希望の人たちを中心とする高校生諸君（４）&#xD;
摂食障害の自助グループなどが催す会に集まった人たち（５）&#xD;
摂食障害に関係する専門職の学会のシンポジウム聴講者（６，７）&#xD;
違った対象の方々への講演でも全く同じ内容が出てくることがありますが、それは違った面から眺めていることでもありますので、その重複部分をそのまま載せていることをご了解ください。プロジェクターで図を示しながら話した講演については、その図がなくても理解できるように、少し書き直したところがあることもご了解ください。
&lt;br/&gt;
&lt;br/&gt;目次: １ 不安の時代の家族と、その中の思春期の子ども p.2 -- ２ いのち・脳・こころ p.14 -- ３ 意識の世界と無意識の世界：心の神経機構に迫る p.24 -- ４ 摂食の調節とその異常：肥満、ダイエット、拒・過食症 p.34 -- ５ 拒食・過食の人達が伝えようとしていること、その人達に伝えたいこと p.43 -- ６ 共依存を考える p.58 -- ７ 摂食障害の自助グループにおける共感：それは傷の舐めあいか？ p.62</description>
      <pubDate>Thu, 29 Oct 2009 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Higher body mass index is a predictor of death among professional sumo wrestlers</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/126</link>
      <description>タイトル: Higher body mass index is a predictor of death among professional sumo wrestlers
&lt;br/&gt;
&lt;br/&gt;著者: Kanda, Hideyuki; Hayakawa, Takehito; Tsuboi, Satoshi; Mori, Yayoi; Takahashi, Teruna; Fukushima, Tetsuhito
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Journal of Sports Science and Medicine
&lt;br/&gt;
&lt;br/&gt;巻: 8
&lt;br/&gt;
&lt;br/&gt;号: 4
&lt;br/&gt;
&lt;br/&gt;開始ページ: 711
&lt;br/&gt;
&lt;br/&gt;終了ページ: 712</description>
      <pubDate>Mon, 30 Nov 2009 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>High Serum Level of Neopterin is a Risk Factor of Patients with Heart Failure</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/125</link>
      <description>タイトル: High Serum Level of Neopterin is a Risk Factor of Patients with Heart Failure
&lt;br/&gt;
&lt;br/&gt;著者: Sasaki, Toshiki; Takeishi, Yasuchika; Suzuki, Satoshi; Niizeki, Takeshi; Kitahara, Tatsuro; Katoh, Shigehiko; Ishino, Mitsunori; Shishido, Tetsuro; Watanabe, Tetsu; Kubota, Isao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: International Journal of Cardiology
&lt;br/&gt;
&lt;br/&gt;巻: 145
&lt;br/&gt;
&lt;br/&gt;号: 2
&lt;br/&gt;
&lt;br/&gt;開始ページ: 318
&lt;br/&gt;
&lt;br/&gt;終了ページ: 318
&lt;br/&gt;
&lt;br/&gt;抄録: Serum neopterin concentration was measured in 198 patients with chronic heart failure (CHF) and 62 control subjects by ELISA. Patients were prospectively followed during a median follow-up period of 745 days with end points of cardiac death or re-hospitalization due to progressive heart failure. Serum concentration of neopterin increased with advancing New York Heart Association (NYHA) functional class (P &lt; 0.001). High neopterin group had a significantly higher incidence of cardiac events than low neopterin group (P &lt; 0.0001). In the multivariate Cox analysis, serum neopterin concentration was an independent risk factor for cardiac events (hazard ratio 1.70, 95%CI 1.16-2.50, P = 0.0068). Serum neopterin concentration is a novel prognostic marker for CHF.</description>
      <pubDate>Thu, 18 Nov 2010 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/124</link>
      <description>タイトル: High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice
&lt;br/&gt;
&lt;br/&gt;著者: Kitahara, Tatsuro; Takeishi, Yasuchika; Harada, Mutsuo; Niizeki, Takeshi; Suzuki, Satoshi; Sasaki, Toshiki; Ishino, Mitsunori; Bilim, Olga; Nakajima, Osamu; Kubota, Isao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Cardiovascular Research
&lt;br/&gt;
&lt;br/&gt;巻: 80
&lt;br/&gt;
&lt;br/&gt;号: 1
&lt;br/&gt;
&lt;br/&gt;開始ページ: 40
&lt;br/&gt;
&lt;br/&gt;終了ページ: 46
&lt;br/&gt;
&lt;br/&gt;抄録: Aim: High-mobility group box 1 (HMGB1) is a nuclear DNA-binding protein and is released from necrotic cells, inducing inflammatory responses and promoting tissue repair and angiogenesis. To test the hypothesis that HMGB1 enhances angiogenesis and restores cardiac function after myocardial infarction, we generated transgenic mice with cardiac specific overexpression of HMGB1 (HMGB1-Tg) using α-myosin heavy chain (MHC) promoter. Methods and Results: The left anterior descending coronary artery was ligated in HMGB1-Tg and wild-type littermate (Wt) mice. After coronary artery ligation, HMGB1 was released into circulation from the necrotic cardiomyocytes of HMGB1 overexpressing hearts. The size of myocardial infarction was smaller in HMGB1-Tg than in Wt mice. Echocardiography and cardiac catheterization demonstrated that cardiac remodeling and dysfunction after myocardial infarction were prevented in HMGB1-Tg mice compared to Wt mice. Furthermore, survival rate after myocardial infarction of HMGB1-Tg mice was higher than that of Wt mice. Immunohistochemical staining revealed that capillary and arteriole formations after myocardial infarction were enhanced in HMGB1-Tg mice. Conclusions: We demonstrated the first in vivo evidence that HMGB1 enhances angiogenesis, restores cardiac function, and improves survival after myocardial infarction. These results may provide a novel therapeutic approach for left ventricular dysfunction after myocardial infarction.</description>
      <pubDate>Tue, 30 Sep 2008 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Pentosidine and soluble receptor for advanced glycation end-product (RAGE) are important prognostic factors independent of renal function in heart failure</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/123</link>
      <description>タイトル: Pentosidine and soluble receptor for advanced glycation end-product (RAGE) are important prognostic factors independent of renal function in heart failure
&lt;br/&gt;
&lt;br/&gt;著者: Takeishi, Yasuchika; Koyama, Yo
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Journal of Cardiac Failure
&lt;br/&gt;
&lt;br/&gt;巻: 14
&lt;br/&gt;
&lt;br/&gt;号: 7
&lt;br/&gt;
&lt;br/&gt;開始ページ: 627
&lt;br/&gt;
&lt;br/&gt;終了ページ: 628
&lt;br/&gt;
&lt;br/&gt;注記: Letter to the Editor</description>
      <pubDate>Fri, 29 Aug 2008 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Soluble Receptor for Advanced Glycation End Products (RAGE) is a Prognostic Factor for Heart Failure</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/122</link>
      <description>タイトル: Soluble Receptor for Advanced Glycation End Products (RAGE) is a Prognostic Factor for Heart Failure
&lt;br/&gt;
&lt;br/&gt;著者: Koyama, Yo; Takeishi, Yasuchika; Niizeki, Takeshi; Suzuki, Satoshi; Kitahara, Tatsuro; Sasaki, Toshiki; Kubota, Isao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Journal of Cardiac Failure
&lt;br/&gt;
&lt;br/&gt;巻: 14
&lt;br/&gt;
&lt;br/&gt;号: 2
&lt;br/&gt;
&lt;br/&gt;開始ページ: 133
&lt;br/&gt;
&lt;br/&gt;終了ページ: 139
&lt;br/&gt;
&lt;br/&gt;抄録: Background: We recently reported that serum levels of pentosidine, one of the well defined advanced glycation end products (AGE), was an independent prognostic factor for heart failure. Receptor for AGEs (RAGE) is expressed in a variety of tissues, and RAGE has a C-truncated secretory isoform of the receptor protein, termed soluble RAGE. In the present study, we measured serum soluble RAGE levels in patients and examined whether serum soluble RAGE predicts prognosis in patients with heart failure. Methods and Results: Serum soluble RAGE concentration was measured in 160 patients with heart failure by a competitive enzyme-linked immunosorbent assay. Patients were prospectively followed during a median follow-up period of 872 days with endpoints of cardiac death or re-hospitalization. Serum soluble RAGE level increased with advancing NYHA functional class. Serum soluble RAGE level was also higher in patients with cardiac events than in event free patients. From the receiver operating characteristic (ROC) curve analysis, the cut-off value of serum soluble RAGE level was determined as 1220 pg/ml. Kaplan-Meier analysis clearly demonstrated that the high soluble RAGE group had a significantly higher incidence of cardiac events than occurred in the low serum soluble RAGE group (P = 0.0004). In the multivariate Cox proportional hazard analysis, soluble RAGE and serum pentosidine were independent risk factors for cardiac events (soluble RAGE: HR 1.90, 95% CI 1.16 . 3.09, P = 0.010; pentosidine: HR 1.59, 95% CI 1.11 . 2.29, P = 0.012). Conclusions: Serum soluble RAGE level is an independent prognostic factor for heart failure, and this novel marker may be useful for risk stratification of patients with heart failure.</description>
      <pubDate>Wed, 27 Feb 2008 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/121</link>
      <description>タイトル: Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure
&lt;br/&gt;
&lt;br/&gt;著者: Suzuki, Satoshi; Takeishi, Yasuchika; Niizeki, Takeshi; Koyama, Yo; Kitahara, Tatsuro; Sasaki, Toshiki; Sagara, Mina; Kubota, Isao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: American Heart Journal
&lt;br/&gt;
&lt;br/&gt;巻: 155
&lt;br/&gt;
&lt;br/&gt;号: 1
&lt;br/&gt;
&lt;br/&gt;開始ページ: 75
&lt;br/&gt;
&lt;br/&gt;終了ページ: 81
&lt;br/&gt;
&lt;br/&gt;抄録: Background: Pentraxin 3 (PTX3) is a novel inflammatory marker produced by endothelial cells, smooth muscle cells and macrophages. The purpose of the present study was to examine the clinical significance of plasma PTX3 levels in patients with heart failure. Methods: We measured plasma PTX3 levels in 196 patients with heart failure and 60 control subjects without heart failure by sandwich ELISA. Patients were prospectively followed during a median follow-up period of 655 days with the end points of cardiac death or progressive heart failure requiring re-hospitalization. Results: Plasma PTX3 concentrations were higher in patients with heart failure than in control subjects (P &lt; 0.0001) and increased as the severity of NYHA functional class advanced (P &lt; 0.0001). A total of 63 cardiac events occurred during a follow-up period, and cardiac event free rate was markedly lower in patients with high PTX3 levels than in those with normal PTX3 levels (44.7% vs. 89.2%, P &lt; 0.0001). The multivariate Cox proportional hazard analysis demonstrated that plasma PTX3 level, but not high sensitive C-reactive protein, was the independent predictor of cardiac events (hazard ratio 1.20, 95% confidence interval 1.03-1.40, P = 0.0162). Patients were divided into 4 groups based on plasma PTX3 values from 1st to 4th quartile. The highest 4th quartile of plasma PTX3 levels was associated with the highest risk of cardiac events (9.23-fold compared to the 1st quartile). Conclusions: Plasma PTX3 level provides important prognostic information for the risk stratification of patients with heart failure.</description>
      <pubDate>Sat, 29 Dec 2007 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/120</link>
      <description>タイトル: Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels
&lt;br/&gt;
&lt;br/&gt;著者: Takeishi, Yasuchika; Toriyama, Sayumi; Takabatake, Noriaki; Shibata, Yoko; Konta, Tsuneo; Emi, Mitsuru; Kato, Takeo; Kawata, Sumio; Kubota, Isao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Biochemical and Biophysical Research Communications
&lt;br/&gt;
&lt;br/&gt;巻: 362
&lt;br/&gt;
&lt;br/&gt;号: 2
&lt;br/&gt;
&lt;br/&gt;開始ページ: 480
&lt;br/&gt;
&lt;br/&gt;終了ページ: 484
&lt;br/&gt;
&lt;br/&gt;抄録: Background: Brain natriuretic peptide (BNP) has been widely used for the diagnosis and prognostic evaluation of chronic heart failure (CHF). In the present study, we performed association study of single nucleotide polymorphisms (SNPs) surrounding the natriuretic peptide precursor B (NPPB) gene with plasma BNP levels in 2970 adult Japanese. Methods and Results: Association analysis between SNPs of the NPPB gene and plasma BNP revealed significant associations of the 8 SNPs surrounding the entire NPPB gene with plasma BNP levels. For instance, as to SNP rs198389 (T-381C), plasma BNP levels among the three genotypic categories, i.e., 2189 homozygous T-allele carriers (BNP 26.4 + 0.6 pg/ml), 697 heterozygous carriers (35.0 + 1.1 pg/ml) and 52 homozygous C-allele carriers (46.0 + 4.1 pg/ml) indicated a co-dominant effect of the minor C-allele on elevating plasma BNP levels (P &lt; 0.0001). Linkage disequilibrium (LD) analysis among the 8 SNPs revealed that the region consisted of two, 5’ major and 3’ minor, LD blocks. Haplotype-based association analysis demonstrated that plasma BNP levels were associated closely with the haplotypes-1 and -2 of the major LD block. Conclusion: These results suggest that genetic variation at the primary locus NPPB gene, represented by definition of risk haplotypes, may be an important determinant of plasma BNP levels.</description>
      <pubDate>Thu, 18 Oct 2007 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Role of diacylglycerol kinase in cellular regulatory processes: A new regulator for cardiomyocyte hypertrophy</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/119</link>
      <description>タイトル: Role of diacylglycerol kinase in cellular regulatory processes: A new regulator for cardiomyocyte hypertrophy
&lt;br/&gt;
&lt;br/&gt;著者: Takeishi, Yasuchika; Goto, Kaoru; Kubota, Isao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Pharmacology &amp; Therapeutics
&lt;br/&gt;
&lt;br/&gt;巻: 115
&lt;br/&gt;
&lt;br/&gt;号: 3
&lt;br/&gt;
&lt;br/&gt;開始ページ: 352
&lt;br/&gt;
&lt;br/&gt;終了ページ: 359
&lt;br/&gt;
&lt;br/&gt;抄録: Diacylglycerol kinase (DGK) phosphorylates and converts diacylglycerol (DAG) to phosphatidic acid. DGK regulates cellular DAG levels and attenuates DAG signaling. The ten mammalian DGK isoforms have been identified to date. In cardiac myocytes, DGKα, ε, and ζ are expressed, and DGKζ is the predominant isoform. DGKζ inhibits protein kinase C activation and subsequent hypertrophic programs in response to endothelin-1 in neonatal rat cardiomyocytes. DGKζ blocks cardiac hypertrophy induced by G protein-coupled receptor agonists and pressure-overload in vivo. DGKζ attenuates ventricular remodeling and improves survival after myocardial infarction. These data provide a novel insight for subcellular mechanisms of cardiac hypertrophy and heart failure, and DGKζ may be a new therapeutic target to prevent cardiac hypertrophy and progression to heart failure.</description>
      <pubDate>Wed, 29 Aug 2007 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>High Serum Level of Pentosidine, an Advanced Glycation End Product (AGE), is a Risk Factor of Patients with Heart Failure</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/118</link>
      <description>タイトル: High Serum Level of Pentosidine, an Advanced Glycation End Product (AGE), is a Risk Factor of Patients with Heart Failure
&lt;br/&gt;
&lt;br/&gt;著者: Koyama, Yo; Takeishi, Yasuchika; Arimoto, Takanori; Niizeki, Takeshi; Shishido, Tetsuro; Takahashi, Hiroki; Nozaki, Naoki; Hirono, Osamu; Tsunoda, Yuichi; Nitobe, Joji; Watanabe, Tetsu; Kubota, Isao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Journal of Cardiac Failure
&lt;br/&gt;
&lt;br/&gt;巻: 13
&lt;br/&gt;
&lt;br/&gt;号: 3
&lt;br/&gt;
&lt;br/&gt;開始ページ: 199
&lt;br/&gt;
&lt;br/&gt;終了ページ: 206
&lt;br/&gt;
&lt;br/&gt;抄録: Background: Pentosidine, one of the advanced glycation end products (AGE), is generated by nonenzymatic glycation and oxidation of proteins. The receptor of AGE (RAGE) is expressed in a variety of tissue, and interaction of AGE with RAGE induces oxidative stress and activation of intracellular signaling causing production of cytokines and mediators of inflammation. We investigated whether serum pentosidine is a risk factor for heart failure. Methods: Serum pentosidine concentration was measured in 141 patients with heart failure and 18 control subjects by a competitive enzyme-linked immunosorbent assay. Patients were prospectively followed during a median follow-up period of 479 days with endpoints of cardiac death or re-hospitalization. Results: Serum concentration of pentosidine was significantly higher in NYHA class III/IV patients than in NYHA class I/II patients (P &lt; 0.0001). Serum pentosidine was also higher in patients with cardiac events than in event free patients (P &lt; 0.001). In the univariate Cox proportional hazard analysis, age, NYHA class, pentosidine, creatinine, uric acid, B-type natriuretic peptide, left ventricular end-systolic volume and left ventricular mass were significant risk factors to predict cardiac events. In the multivariate Cox analysis, serum pentosidine concentration was an independent risk factor for cardiac events (hazard ratio 1.88, 95% confidence interval 1.23 . 2.69, P = 0.002). Patients were divided into 4 groups based on the serum pentosidine levels. The highest 4th quartile of pentosidine was associated with the highest risk of cardiac events (4.52-fold). Conclusions: Serum pentosidine concentration is an independent prognostic factor for heart failure, and this new marker may be useful for risk stratification of patients with heart failure.</description>
      <pubDate>Thu, 29 Mar 2007 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>How to Create a Natural Nasolabial Fold during Muscle Transplantation for the Treatment of Facial Paralysis</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/117</link>
      <description>タイトル: How to Create a Natural Nasolabial Fold during Muscle Transplantation for the Treatment of Facial Paralysis
&lt;br/&gt;
&lt;br/&gt;著者: Ueda, Kazuki; Kajikawa, Masayuki; Ookouchi, Masayuki; Tateshita, Tohru; Hirose, Tarou; Asai, Emiko; Sakaba, Takao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Journal of Plastic, Reconstructive &amp; Aesthetic Surgery
&lt;br/&gt;
&lt;br/&gt;巻: 63
&lt;br/&gt;
&lt;br/&gt;号: 5
&lt;br/&gt;
&lt;br/&gt;開始ページ: e481
&lt;br/&gt;
&lt;br/&gt;終了ページ: e483
&lt;br/&gt;
&lt;br/&gt;注記: This work was partly presented at the 5th International Muscle Symposium (Vienna, 2000/5/20), entitled "A New Combination of Cross-face Nerve Grafting and Muscle Transplantation for Treatment of Facial Paralysis".; Case Reports: E-only publication</description>
      <pubDate>Wed, 28 Apr 2010 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Delayed and acute hemolytic transfusion reactions due to red cell antibodies and red cell-reactive HLA antibodies</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/19</link>
      <description>タイトル: Delayed and acute hemolytic transfusion reactions due to red cell antibodies and red cell-reactive HLA antibodies
&lt;br/&gt;
&lt;br/&gt;著者: Takeuchi, Chikako; Ohto, Hitoshi; Miura, Saori; Yasuda, Hiroyasu; Ono, Satoshi; Ogata, Takashi
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Transfusion
&lt;br/&gt;
&lt;br/&gt;巻: 45
&lt;br/&gt;
&lt;br/&gt;号: 12
&lt;br/&gt;
&lt;br/&gt;開始ページ: 1925
&lt;br/&gt;
&lt;br/&gt;終了ページ: 1929
&lt;br/&gt;
&lt;br/&gt;抄録: Background：It has been controversial whether HLA antibodies cause hemolytic transfusion reactions (HTR) or shortened RBC survival. We report a patient who had two episodes of HTR, the latter of which was likely due to RBC-reactive HLA antibodies. Case Report：A 77-year-old woman, admitted for gastric varix rupture, had no RBC irregular antibodies detected before transfusion. On hospital day 12, after transfusion of two units of RBCs and two units of FFP, the first delayed hemolytic episode occurred and anti-E, anti-c, anti-Jka and unidentified RBC-reactive antibodies were detected in serum from day 14. Two further units of compatible RBCs were transfused using a leukocyte-reduction filter on days 19 and 22. After 4 hours of starting a transfusion on day 22, the patient had fever, and a second hemolytic episode was recorded. Multireactive HLA antibodies (reactive against 20 of 20 donor panel lymphocytes) were detected in sera from day 15 to day 21. These HLA antibodies reacted strongly with HLA-A2 and HLA-B7 antigens, corresponding to Bgc and Bga antigens on RBCs, respectively. RBCs transfused on day 22 were found to be HLA-A2 by genotyping.&#xD;
Conclusion： Strong HLA alloantibodies in this recipient appear to have caused a HTR. It is suggested that HLA antibodies be considered in patients with unexplained HTRs.</description>
      <pubDate>Mon, 28 Nov 2005 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Survival and recovery of apheresis platelets stored in a polyolefin container with high oxygen permeability</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/18</link>
      <description>タイトル: Survival and recovery of apheresis platelets stored in a polyolefin container with high oxygen permeability
&lt;br/&gt;
&lt;br/&gt;著者: Ezuki, Shoji; Kanno, Takahiro; Ohto, Hitoshi; Herschel, Louise; Ito, Takatoshi; Kawabata, Kinuyo; Seino, Osamu; Ikeda, Kazuhiko; Nollet, Kenneth E
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Vox Sanguinis
&lt;br/&gt;
&lt;br/&gt;巻: 94
&lt;br/&gt;
&lt;br/&gt;号: 4
&lt;br/&gt;
&lt;br/&gt;開始ページ: 292
&lt;br/&gt;
&lt;br/&gt;終了ページ: 298
&lt;br/&gt;
&lt;br/&gt;抄録: Background and Objectives Oxygen permeability is important in platelet storage media. We compared a new polyolefin container with enhanced oxygen permeability (PO-80, Kawasumi, Tokyo, Japan) to a widely used alternative (PL2410, Baxter Healthcare, Illinois, USA). Materials and Methods In vitro characteristics of paired platelet concentrates (PCs, mean 4.2×1011/250 ml plasma/bag) stored in PO-80 or PL2410 were assessed through nine days of storage. In vivo recovery and survival of seven-day-old autologous PCs were assessed according to the Murphy method. Results Laboratory assessment of platelet quality favored PO-80 during nine days of storage with statistically significant differences in glucose consumption (2.75 vs. 4.93 mmol/1012/24hrs in the interval 120-168 hrs), lactate generation (4.37 vs. 8.11 mmol/1012/24hrs in the interval 120-168 hrs), pO2 (59.3 vs. 38.1 mmHg at day 1), and HCO3- (14.7 vs. 13.4 mmol/L at day 1). Statistically significant differences were not seen in aggregation, hypotonic shock response, or pH. In vivo assessment of autologous platelets stored seven days in the PO-80 container revealed that recovery was 82.1% and survival was 81.0% of fresh control. Seven-day-stored PCs in PO-80 were shown in vivo to be noninferior to fresh platelets, with upper confidence limits (UCL95) in recovery and survival of stored PCs below the maximum acceptable difference (MAD); 15.3% UCL95 &lt; 20.4% MAD and 2.1 days UCL95 &lt; 2.1 days MAD. Conclusions The in vitro characteristics of PCs stored in a highly oxygen-permeable container were stable at least seven days. The in vivo study supports the suitability of PO-80 for seven-day platelet storage.</description>
      <pubDate>Mon, 28 Apr 2008 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Culture-based bacterial detection systems for platelets: the effect of time prior to sampling and duration of incubation required for detection using aerobic culture</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/14</link>
      <description>タイトル: Culture-based bacterial detection systems for platelets: the effect of time prior to sampling and duration of incubation required for detection using aerobic culture
&lt;br/&gt;
&lt;br/&gt;著者: Ezuki, Shoji; Kawabata, Kinuyo; Kanno, Takahiro; Ohto, Hitoshi
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Transfusion
&lt;br/&gt;
&lt;br/&gt;巻: 47
&lt;br/&gt;
&lt;br/&gt;号: 11
&lt;br/&gt;
&lt;br/&gt;開始ページ: 2044
&lt;br/&gt;
&lt;br/&gt;終了ページ: 2049
&lt;br/&gt;
&lt;br/&gt;注記: Title of published version: Culture-based bacterial detection systems for platelets: the effect of time prior to sampling and duration of incubation required for detection with aerobic culture
&lt;br/&gt;
&lt;br/&gt;抄録: BACKGROUND: Bacterial contamination of platelet products (PLTs) occurs at low concentrations requiring a period of incubation for growth to minimize sampling error. Culture-based detection methods also need sufficient incubation time; together these periods may limit the useful life of PLTs. This study characterizes the impact of sampling and detection times using two commercially-available bacteria detection products.&#xD;
STUDY DESIGN AND METHODS: Apheresis PLTs inoculated with nine bacterial species at low concentrations were sampled immediately, and after 24 hours following inoculation. Test results were analyzed following incubation at 16, 20 and 24 hours after sampling using two bacterial detection systems. RESULTS: When sampled immediately after inoculation, BacT/ALERT (BioMerieux) and Pall eBDS (Pall Corporation) failed to detect some PLTs inoculated with S. epidermidis, S. liquefaciens or P. aeruginosa and S. epidermidis, S. liquefaciens, B. cereus or P. aeruginosa, respectively. The BacT/ALERT was better at 20 hours (p&lt;0.02), but not at 16 or 24 hours for time 0 sampling. When sampling occurred 24 hours after inoculation, there were no difference between the two systems. CONCLUSION: Results suggest that for either bacteria detection system, holding PLTs for 24 hrs prior to sampling improves the detection sensitivity for PLTs contaminated with low concentrations of bacteria and longer incubation periods improve detection.</description>
      <pubDate>Mon, 29 Oct 2007 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Sucrose radical-production cross section regarding heavy-ion irradiation</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/16</link>
      <description>タイトル: Sucrose radical-production cross section regarding heavy-ion irradiation
&lt;br/&gt;
&lt;br/&gt;著者: Nakagawa, Kouichi; Ikota, Nobuo; Anzai, Kazunori
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
&lt;br/&gt;
&lt;br/&gt;巻: 69
&lt;br/&gt;
&lt;br/&gt;号: 5
&lt;br/&gt;
&lt;br/&gt;開始ページ: 1384
&lt;br/&gt;
&lt;br/&gt;終了ページ: 1387
&lt;br/&gt;
&lt;br/&gt;抄録: We investigated the sucrose radical-production cross section induced by heavy-ion irradiation. L-alanine was also used in order to compare radical yield and cross section. The stable free radicals after irradiation were analyzed by EPR (electron paramagnetic resonance). The radical yield obtained by the irradiated samples had a logarithmic correlation with the LET (linear energy transfer). Quantitative EPR analyses showed that radical productions for sucrose and L-alanine vary both by different particle irradiation and the LET under the same absorbed dose. Furthermore, the cross sections of radical productions for samples were calculated. Both cross sections for C ions irradiation under LET 30 [keV/μm] at 50 Gy dose were ~3.0 x 10&lt;sup&gt;-9&lt;/sup&gt; [μm&lt;sup&gt;2&lt;/sup&gt;], taking account of the molecular areas of the samples. The values of the cross sections imply that multiple ionizing particles involve producing stable radicals.</description>
      <pubDate>Mon, 28 Apr 2008 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/15</link>
      <description>タイトル: Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus
&lt;br/&gt;
&lt;br/&gt;著者: Bilim, Olga; Takeishi, Yasuchika; Kitahara, Tatsuro; Arimoto, Takanori; Niizeki, Takeshi; Sasaki, Toshiki; Goto, Kaoru; Kubota, Isao
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Cardiovascular Diabetology
&lt;br/&gt;
&lt;br/&gt;巻: 4
&lt;br/&gt;
&lt;br/&gt;開始ページ: 2
&lt;br/&gt;
&lt;br/&gt;抄録: BACKGROUND: Activation of the diacylglycerol (DAG)-protein kinase C (PKC) pathway has been implicated in the pathogenesis of a number of diabetic complications. Diacylglycerol kinase (DGK) converts DAG to phosphatidic acid and acts as an endogenous regulator of PKC activity. Akt/PKB is associated with a downstream insulin signaling, and PKCbeta attenuates insulin-stimulated Akt phosphorylation. METHODS AND RESULTS: We examined transgenic mice with cardiac-specific overexpression of DGKzeta (DGKzeta-TG) compared to wild type (WT) mice in streptozotocin-induced (STZ, 150 mg/kg) diabetic and nondiabetic conditions. After 8 weeks, decreases in heart weight and heart weight/body weight ratio in diabetic WT mice were inhibited in DGKzeta-TG mice. Echocardiography at 8 weeks after STZ-injection demonstrated that decreases in left ventricular end-diastolic diameter and fractional shortening observed in WT mice were attenuated in DGKzeta-TG mice. Thinning of the interventricular septum and the posterior wall in diabetic WT hearts were blocked in DGKzeta-TG mice. Reduction of transverse diameter of cardiomyocytes isolated from the left ventricle in diabetic WT mice was attenuated in DGKzeta-TG mice. Cardiac fibrosis was much less in diabetic DGKzeta-TG than in diabetic WT mice. Western blots showed translocation of PKCbeta and delta isoforms to membrane fraction and decreased Akt/PKB phosphorylation in diabetic WT mouse hearts. However in diabetic DGKzeta-TG mice, neither translocation of PKC nor changes Akt/PKB phosphorylation was observed. CONCLUSION: DGKzeta modulates intracellular signaling and improves the course of diabetic cardiomyopathy. These data may suggest that DGKzeta is a new therapeutic target to prevent or reverse diabetic cardiomyopathy.</description>
      <pubDate>Sun, 03 Feb 2008 22:58:59 GMT</pubDate>
    </item>
    <item>
      <title>Guidelines for managing conscientious objection to blood transfusion</title>
      <link>http://ir.fmu.ac.jp/dspace/handle/123456789/17</link>
      <description>タイトル: Guidelines for managing conscientious objection to blood transfusion
&lt;br/&gt;
&lt;br/&gt;著者: Ohto, Hitoshi; Yonemura, Yuji; Takeda, Junzo; Inada, Eiichi; Hanada, Ryoji; Hayakawa, Satoshi; Miyano, Takeshi; Kai, Katsunori; Iwashi, Waichiro; Muto, Kaori; Asai, Fumikazu
&lt;br/&gt;
&lt;br/&gt;誌名/書名: Transfusion Medicine Reviews
&lt;br/&gt;
&lt;br/&gt;巻: 23
&lt;br/&gt;
&lt;br/&gt;号: 3
&lt;br/&gt;
&lt;br/&gt;開始ページ: 221
&lt;br/&gt;
&lt;br/&gt;終了ページ: 228
&lt;br/&gt;
&lt;br/&gt;抄録: Parents sometimes deny their children blood transfusion because of&#xD;
their religious beliefs. The Japanese Joint Committee on the Refusal of Blood Transfusion on Religious Grounds asserts that the health and life of every child under 15 years of age should be guarded by the collective efforts of health, welfare and advocacy institutions when a parent or guardian seeks to withhold transfusion therapy. Patients 18 years or older should receive treatment without transfusion after signing and submitting a "Certificate of Refusal Blood Transfusion and&#xD;
Exemption from Liability". For a patient younger than 18, but 15 years or older, essential transfusion can be performed if the patient or at least one guardian consents. Without patient or guardians consent, guidelines for patients 18 years or older shall apply. Healthcare providers should offer the best possible care that is consistent with a patient’s age and competency.</description>
      <pubDate>Sun, 28 Jun 2009 22:58:59 GMT</pubDate>
    </item>
  </channel>
</rss>


